Skip to main content

Table 3 Correlations between CAR, PLR and clinicopathological characteristics of patients

From: Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer

Variables

CAR

p value

PLR

p value

Low

High

Low

High

n

%

n

%

n

%

n

%

Age (years)

  ≤ 68

115

54.5

2

14.3

 

74

52.5

43

51.2

 

  > 68

96

45.5

12

85.7

0.004

67

47.5

41

48.8

0.851

Sex

 Male

136

64.5

11

78.6

 

99

70.2

48

57.1

 

 Female

75

35.5

3

21.4

0.389

42

29.8

36

42.9

0.046

BMI (kg/m2)

 Low (≤21.9)

105

49.8

9

64.3

 

61

43.3

53

63.1

 

 High (> 21.9)

106

50.2

5

35.7

0.293

80

56.7

31

36.9

0.004

Performance status

 0

161

76.3

6

42.9

 

107

75.9

60

71.4

 

 1–3

50

23.7

8

57.1

0.006

34

24.1

24

28.6

0.460

Location

 U/M/L

197

93.4

12

85.7

 

132

93.6

77

91.7

 

 Whole

14

6.6

2

14.3

0.261

9

6.4

7

8.3

0.582

Macroscopic type

 Type 0/1/2

59

28.0

2

14.3

 

41

29.1

20

23.8

 

 Type 3/4/5

152

72.0

12

85.7

0.361

100

70.9

64

76.2

0.390

Operative procedure

 Distal gastrectomy

110

52.1

7

50.0

 

72

51.1

45

53.6

 

 Total gastrectomy

101

47.9

7

50.0

0.877

69

48.9

39

46.4

0.716

Lymph node dissection

 D1

30

14.2

2

14.3

 

19

13.5

13

15.5

 

 D2

181

85.8

12

85.7

1.000

122

86.5

71

84.5

0.678

Histology

 Differentiated

91

43.1

6

42.9

 

58

41.1

39

46.4

 

 Undifferentiated

120

56.9

8

57.1

0.984

83

58.9

45

53.6

0.438

Lymphatic invasion

 Absent

18

8.5

1

7.1

 

13

9.2

6

7.1

 

 Present

193

91.5

13

92.9

1.000

128

90.8

78

92.9

0.588

Venous invasion

 Absent

150

71.1

6

42.9

 

102

72.3

54

64.3

 

 Present

61

28.9

8

57.1

0.027

39

27.7

30

35.7

0.205

TNM sub-stage

 IIIA

77

36.5

3

21.4

 

54

38.3

26

31.0

 

 IIIB

69

32.7

3

21.4

 

41

29.1

31

36.9

 

 IIIC

55

26.1

8

57.1

0.125

46

32.6

27

32.1

0.404

Tumor size (mm)

  ≤ 60

112

53.1

3

21.4

 

84

59.6

31

36.9

 

  > 60

99

46.9

11

78.6

0.027

57

40.4

53

63.1

0.001

Adjuvant chemotherapy

 Absent

37

17.5

4

28.6

 

29

20.6

12

14.3

 

 Present

174

82.5

10

71.4

0.292

112

79.4

72

85.7

0.238

CAR

 Low (≤0.47)

     

139

98.6

72

85.7

 

 High (> 0.47)

     

2

1.4

12

14.3

< 0.001

NLR

 Low (≤1.90)

98

46.4

1

7.1

 

85

60.3

14

16.7

 

 High (> 1.90)

113

53.6

13

92.9

0.004

56

39.7

70

83.3

< 0.001

PLR

 Low (≤172)

139

65.9

2

85.7

      

 High (> 172)

72

34.1

12

85.7

< 0.001

     

PNI

 Low (≤45.6)

78

37.0

12

85.7

 

37

26.2

53

63.1

 

 High (> 45.6)

133

63.0

2

14.3

< 0.001

104

73.8

31

36.9

< 0.001

GPS

 0

171

81.0

0

0

 

115

81.6

56

66.7

 

 1/2

40

19.0

14

100

< 0.001

26

18.4

28

33.3

0.011

PI

 0

205

97.2

0

0

 

135

95.7

70

83.3

 

 1/2

6

2.8

14

100

< 0.001

6

4.3

14

16.7

0.002

Recurrence

 Absent

113

53.6

4

28.6

 

80

56.7

37

44.0

 

 Present

98

46.4

10

71.4

0.097

61

43.3

47

56.0

0.065

  1. BMI body mass index, PS performance status, TNM tumor-node-metastasis, CAR C-reactive protein/Albumin ratio, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, PNI Prognostic Nutritional Index, GPS Glasgow Prognostic Score, PI prognostic index